bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 35,000 shares of bluebird bio stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total transaction of $5,298,300.00. Following the completion of the transaction, the insider now directly owns 62,305 shares of the company’s stock, valued at approximately $9,431,730.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

bluebird bio, Inc. (BLUE) traded up $13.30 during mid-day trading on Friday, reaching $156.25. 1,240,575 shares of the company traded hands, compared to its average volume of 863,731. bluebird bio, Inc. has a 1-year low of $41.25 and a 1-year high of $164.80.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter last year, the firm posted ($2.07) earnings per share. bluebird bio’s revenue was up 397.4% compared to the same quarter last year. analysts forecast that bluebird bio, Inc. will post -6.78 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 35,000 Shares of Stock” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/bluebird-bio-inc-blue-insider-jeffrey-t-walsh-sells-35000-shares-of-stock/1678595.html.

Institutional investors have recently modified their holdings of the business. QS Investors LLC raised its position in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 500 shares in the last quarter. Bank of Montreal Can raised its position in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 911 shares in the last quarter. Turner Investments LLC bought a new stake in bluebird bio in the second quarter worth about $184,000. SG Americas Securities LLC raised its position in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. bought a new stake in bluebird bio in the second quarter worth about $210,000.

A number of equities analysts have commented on BLUE shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $108.00 price objective on shares of bluebird bio in a report on Friday, August 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a report on Friday, August 11th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $186.00 price target on shares of bluebird bio in a report on Friday, October 6th. Maxim Group reissued a “buy” rating and set a $170.00 price target (up previously from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Finally, BTIG Research raised shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price target for the company in a report on Thursday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company. bluebird bio currently has a consensus rating of “Buy” and an average price target of $131.05.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.